Signal quality first. Marketing name last.
The open question was never whether the body produces measurable mechanical signals. It was which features are repeatable, meaningful and useful for a defined purpose. That gets answered in order: signal quality, then repeatability, then sensitivity and specificity to context, then agreement with an established ground-truth reference, then performance in a defined population and use case.
This page states where each claim currently sits in that order, and what it would take to move.
Registered human trials
The following studies are registered on ClinicalTrials.gov. The timescale column ties each one back to the fast, slow and slowest framing: this is a programme, not a scatter.
| Study | Identifier | Timescale class |
|---|---|---|
| imPulse® UNA Infrasound-to-Ultrasound E-Stethoscope | NCT04941209 | Platform |
| imPulse® UNA Full-Spectrum, Over-Clothing E-Stethoscope | NCT04556149 | Platform |
| Vibroacoustic Study of Lung Development in Newborn Infants | NCT05827250 | Slowest — developmental |
| SARS-CoV-2/COVID-19 Study of Next-Generation Non-Invasive Passive Detection Technologies | NCT05765396 | Fast — acute infectious |
| Rapid Research in Diagnostics Development for TB Network | NCT04923958 | Fast — acute infectious |
| imPulse™ Tor System Self-Directed Cuffless Blood Pressure Monitoring | NCT05386654 | Slow — cardiovascular |
Scale of the human data foundation
Across these programs the human-data foundation exceeds 20,000 participants. Acquisition is fully passive throughout, and no device-related adverse events have been reported.
That data has been collected across three timescales — acute infectious, non-communicable cardiopulmonary and gut, and maternal and fetal — at leading clinical research centers.
Not one study. A swarm.
2,500 510(k)-exempt imPulse® UNA units have completed manufacturing and are deploying into global registered heart, lung and gut programs spanning all three timescales — infectious, non-communicable and chronic. The aim is a reference atlas: what coherence decoupling looks like by disease, age, sex and condition, and what departure precedes deterioration.
The genome needed a map before it became useful. So does the vibrome.
Partners
Vibrome® data collection and validation has been conducted in collaboration with the Gates Foundation, the Clinton Health Access Initiative, the U.S. Department of Defense including the USAF 59th Medical Wing, the Uniformed Services University of the Health Sciences, Johns Hopkins University, the University of California San Francisco, and Georgetown University Medical Center. The inaugural COVID-19 clinical study at Johns Hopkins was sponsored by Schmidt Futures.
Regulatory status
The imPulse® UNA transducer platform is registered and listed with the FDA under product code DQC, listing ID 922165. That listed platform is the Point-of-Need sensing core. Point-of-Habitat® is a zero-effort longevity configuration of the same technology, extending the core in four respects: noise floor and signal conditioning, multimodal sensor hardware, edge inference, and cross-signal validation. Listing is not clearance or approval, and no Vibrome®-derived index is currently cleared or approved as a diagnostic.
Current positioning is early detection, triage and wellness monitoring. Disease decision-support requires its own regulatory pathway. US policy distinguishes general wellness functionality from software intended to diagnose, treat, mitigate or prevent disease, and we position accordingly.
Claim and evidence table
Each row states where the claim sits and where it comes from, so a reader can check it rather than take it.
The body generates mechanical signals
Cardiac mechanical motion can be sensed externally
Signal morphology changes with respiration and exertion
The signal is detectable through clothing
Acquisition scales outside a laboratory
Recovery dynamics carry information about resilience
42ndMovement™ quantifies healthspan
The limits, stated plainly.
- Longevity is not a validated surrogate endpoint — not for Vibrome® and not for any other technology. Earning that validation is the work ahead, not a claim behind us.
- Evidence for disease-state discrimination is not evidence for longevity measurement. We report them separately and ask that they be read separately.
- No Vibrome®-derived index is currently cleared or approved as a diagnostic.
These constraints shape every study we design, and we would rather state them than discover them with a partner mid-protocol.